The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors

Pituitary

Volumn 5, Issue 4, 2002, Pages 235-242

  Musat, Madalina ^a,b   Korbonits, Márta ^a   Pyle, Megan ^a   Gueorguiev, Maria ^a   Kola, Blerina ^a   Morris, Damian G ^a   Powell, Michael ^c   Dumitrache, Constantin ^b   Poiana, Catalina ^b   Grossman, Ashley B ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cell cycle; Pituitary adenomas; S phase kinase interacting protein 2; Skp2

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; PROTEASOME; PROTEIN KINASE; PROTEIN P27; S PHASE KINASE INTERACTING PROTEIN 2; UBIQUITIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; SAMPLING;

ADENOMA; ADULT; AGED; CELL CYCLE PROTEINS; DNA PRIMERS; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; MUSCLE PROTEINS; PITUITARY NEOPLASMS; PROLACTINOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 0141615613     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025325832698     Document Type: Article

References (31)

1. Nakayama K, Ishida N, Shirane M et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-720.
2. Kiyokawa H, Kineman RD, Manova-Todorova KO et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996;85:721-732.
3. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998;396:177-180.
4. Jin L, Qian X, Kulig E et al. Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip 1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol 1997;151:509-519.
5. Qian X, Jin L, Grande JP, Lloyd RV. Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 1996-1137:3051-3060.
6. Lidhar K, Korbonits M, Jordan S et al. Low expression of the cell cycle inhibitor p27Kip 1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. J Clin Endocrinol Metab 1999;84:3823-3830.
7. Dahia PL, Aguiar RC, Honegger J et al. Mutation and expression analysis of the p27/kip 1 gene in corticotrophin-secreting tumours. Oncogene 1998;16:69-76.
8. Kip1 protein and Jab1 (Jun activation domain-binding protein 1) in human pituitary tumors. J Clin Endocrinol Metab 2002;8:2635-2643.
9. Hershko A, Ciechanover A, Varshavsky A. Basic Medical Research Award. The ubiquitin system. Nat Med 2000;6:1073-1081.
10. Zhang H, Kobayashi R, Galaktionov K, Beach D. p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 1995;82:915-925.
11. Hershko D, Bornstein G, Ben Izhak O et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001;91:1745-1751.
12. Schulman BA, Carrano AC, Jeffrey PD et al. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature 2000;408:381-386.
13. Sutterluty H, Chatelain E, Marti A et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1:207-214.
14. Demetrick DJ, Zhang H, Beach DH. Chromosomal mapping of the genes for the human CDK2/cyclin A-associated proteins p19 (SKP1A and SKP1B) and p45 (SKP2). Cytogenet Cell Genet 1996;73:104-107.
15. Gstaiger M, Jordan R, Lim M et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001;98:5043-5048.
16. Latres E, Chiarle R, Schulman BA et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 2001;98:2515-2520.
17. Lin R, Wang TT, Miller WH Jr, White JH. Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells. Endocrinology 2003;144:749-753.
18. Korbonits M, Chitnis MM, Norman D et al. The release of leptin and its effect on hormone release from human pituitary adenomas. Clin Endocrinol (Oxf) 2001;54:781-789.
19. Mori M, Mimori K, Shiraishi T et al. p27 expression and gastric carcinoma. Nat Med 1997;3:593
20. Loda M, Cukor B, Tam SW et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-234.
21. Catzavelos C, Bhattacharya N, Ung YC et al. Decreased levels of the cell cycle inhibitor p27/kip1 protein: Prognostic implications in primary breast cancer. Nat Med 1997;3:227-230.
22. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-199.
23. Marti A, Wirbelauer C, Scheffner M, Krek W, Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1999;1:14-19.
24. Nakayama K, Nagahama H, Minamishima YA et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 2000;19:2069-2081.
25. Signoretti S, Di Marcotullio L, Richardson A et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110:633-641.
26. Yang G, Ayala G, Marzo AD et al. Elevated Skp2 protein expression in human prostate cancer: Association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002;8:3419-3426.
27. Penin RM, Fernandez-Figueras MT, Puig L, Rex J, Ferrandiz C, Ariza A. Over-expression of p45(SKP2) in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27(KIP1) down-regulation. Mod Pathol 2002; 15:1227-1235.
28. Lim MS, Adamson A, Lin Z et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: Correlation with p27(Kip1) and proliferation index. Blood 2002;100:2950-2956.
29. Hirai A, Nakamura S, Noguchi Y et al. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 1997;272:13-16.
30. Malek NP, Sundberg H, McGrew S et al. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 2001-1413:323-327.
31. Hara T, Kamura T, Nakayama K, Oshikawa K, Hatakeyama S, Nakayama K. Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J Biol Chem 2001;276:48937-48943.